Cargando…

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

BACKGROUND: Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tartof, Sara Y, Slezak, Jeff M, Fischer, Heidi, Hong, Vennis, Ackerson, Bradley K, Ranasinghe, Omesh N, Frankland, Timothy B, Ogun, Oluwaseye A, Zamparo, Joann M, Gray, Sharon, Valluri, Srinivas R, Pan, Kaije, Angulo, Frederick J, Jodar, Luis, McLaughlin, John M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489881/ https://www.ncbi.nlm.nih.gov/pubmed/34619098 http://dx.doi.org/10.1016/S0140-6736(21)02183-8

Ejemplares similares

Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
por: Tartof, Sara Y., et al.
Publicado: (2022)

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5
por: Tartof, Sara Y, et al.
Publicado: (2022)

BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5–11 Years of Age: A Test Negative Design
por: Tartof, Sara Y, et al.
Publicado: (2023)

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
por: Tartof, Sara Y, et al.
Publicado: (2022)

Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants
por: Tartof, Sara Y, et al.
Publicado: (2022)

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study
por: Tartof, Sara Y, et al.
Publicado: (2023)

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years
por: Tartof, Sara Y., et al.
Publicado: (2022)

Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
por: Tartof, Sara Y., et al.
Publicado: (2023)

Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age
por: Khan, Farid L., et al.
Publicado: (2022)

Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
por: Lewnard, Joseph A, et al.
Publicado: (2023)

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine
por: McGrath, Leah J., et al.
Publicado: (2023)

Impact of COVID-19 and effects of BNT162b2 on patient-reported outcomes: quality of life, symptoms, and work productivity among US adult outpatients
por: Di Fusco, Manuela, et al.
Publicado: (2022)

Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron
por: Di Fusco, Manuela, et al.
Publicado: (2023)

Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
por: Haas, Eric J, et al.
Publicado: (2022)

Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system
por: Malden, Deborah E., et al.
Publicado: (2023)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
por: Haas, Eric J, et al.
Publicado: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
por: Singer, Shepherd R., et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
por: Roca, B, et al.
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019–2020
por: Ramirez, Julio A., et al.
Publicado: (2023)

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
por: Prunas, Ottavia, et al.
Publicado: (2022)

Prevention of Coronavirus Disease 2019 Among Older Adults Receiving Pneumococcal Conjugate Vaccine Suggests Interactions Between Streptococcus pneumoniae and Severe Acute Respiratory Syndrome Coronavirus 2 in the Respiratory Tract
por: Lewnard, Joseph A, et al.
Publicado: (2021)

Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study
por: Lewnard, Joseph A, et al.
Publicado: (2022)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Effectiveness of BNT162b2 against COVID-19 in adolescents
por: Powell, Annabel A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b70teefvrs0ctv7dpja29avlqp